← Back to Clinical Trials
Recruiting Phase 2 NCT06852365

Combined Oral Contraceptive Pill and Resistance Starch

Trial Parameters

Condition Metabolic Syndrome
Sponsor University of Pennsylvania
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 100
Sex FEMALE
Min Age 18 Years
Max Age 40 Years
Start Date 2025-06-10
Completion 2028-04
Interventions
wheat dextrinOral Contraceptives, Low-DoseMaltodextrin

Brief Summary

This study will enroll women with PCOS to study the effects of first line therapy, oral contraceptive pills, and then either 12 weeks of resistant starch or 12 weeks of placebo to explore if resistant starch improves cardiometabolic parameters or impacts gut dysbiosis compared to placebo.

Eligibility Criteria

Inclusion Criteria: 1. Women between ages of 18-40 years with BMI greater than or equal to 25 kg/m² to less than or equal to 48 kg/m² diagnosed with PCOS defined by the Rotterdam criteria based on a history of chronic anovulation (8 or fewer periods), androgen excess \[defined as total serum testosterone, free testosterone or a FAI greater than or equal to 90% of the upper limit of normal) or hirsutism (Ferriman-Gallwey score greater than 6 for Hispanics/ Black and greater than or equal to 2 for women of Asian descent)\] and polycystic ovaries as defined by a pelvic ultrasound (20 or more follicles or ovarian vol greater than 10cm3) or elevated AMH. 2. For women with more regular bleeding patterns, but who are suspected to be experiencing periodic anovulatory bleeding, a midluteal progesterone (P4) level less than 3ng/dL will be evidence of ovulatory dysfunction and qualify as anovulation. 3. Women with only hyperandrogenic PCOS phenotype (hyperandrogenism + one more criteria) will be

Related Trials